Compliance as an Explanatory Variable in Hepatitis-C


A Hepatitis C clinical trial program for patients infected with Hepatitis C virus of genotype I demonstrated that the sustained virologic response rate is higher with 48 weeks of Ribavirin in combination with Interferon (I/R) than with 48 weeks of interferon and placebo (UP). The intent-to-treat (ITT) response rate for the I/R group is 29%, versus 9% for the UP group. However, since not all patients completed their treatment, it is likely that the benefit would have been greater if all the patients had taken their full dose for 48 weeks. Assessing the impact of taking the full dose is not trivial; clearly the ITT approach underestimates the response, whereas subsetting the patients who took a large majority of their full dose (eg, 80% of the total dose) likely overestimates the response. Using methodology developed by Efron and Feldman (I), we develop a statistical model that incorporates compliance as a covariate, thereby allowing for an estimate of the fully compliant response rate. It is estimated that the treatment benefit as measured by the difference in sustained virologic response rates of I/R versus UP at full compliance ranged from 23% to 26% compared to 20% for the ITT analysis and 27% for the 80% compliant subgroup.

This is a preview of subscription content, access via your institution.


  1. 1.

    Efron B, Feldman D. Compliance as an explanatory variable in clinical trials (with discussion). J Am Stat Assoc. 1991;86:9–26.

    Article  Google Scholar 

  2. 2.

    Alter MJ. Epidemiology of hepatitis C. Hepatol. 1997;26:62S–65S.

    CAS  Article  Google Scholar 

  3. 3.

    Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis: effects of dose and duration. Hepatol. 1996;24:778–789.

    CAS  Article  Google Scholar 

  4. 4.

    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C. New Engl J Med. 1998;339:1485–1492.

    CAS  Article  Google Scholar 

  5. 5.

    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of Interferon alpha-2b plus Ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352: 1426–1432.

    CAS  Article  Google Scholar 

  6. 6.

    Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clinical Pharmacol Therapeutics. 1995;57:6–15.

    CAS  Article  Google Scholar 

  7. 7.

    Heitjan DF. Ignorability and bias in clinical trials. Stat Med. 1999;18:2421–2434.

    CAS  Article  Google Scholar 

  8. 8.

    Pocock SJ, Abdalla M. The hope and the hazards of using compliance data in randomized controlled trials. Stat Med. 1998;17:303–317.

    CAS  Article  Google Scholar 

  9. 9.

    Lipid Research Clinic Program. The lipid research clinics coronary primary prevention trial results, Parts I and II. JAMA. 1984;251:351–374.

    Article  Google Scholar 

  10. 10.

    McCullagh P, Neider JA. Generalized Linear Models. 2nd Edition. London: Chapman & Hall/CRC; 1989.

    Google Scholar 

  11. 11.

    Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Education Psychol. 1974;66:658–701.

    Article  Google Scholar 

  12. 12.

    Holland P. Statistics and causal inference (with discussion). J Am Stat Assoc. 1986;81:945–970.

    Article  Google Scholar 

  13. 13.

    Hastie TJ, Tibshirani RJ. Generalized Additive Models. London: Chapman & Hall/CRC; 1990.

    Google Scholar 

  14. 14.

    Knight K. Mathematical Statistics. London: Chapman & Hall/CRC; 2000.

    Google Scholar 

  15. 15.

    Chambers JM, Hastie TJ. Statistical Models in S. London: Chapman & Hall; 1991.

    Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Carmen Mak PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mak, C., Heft, S.M., Amkraut, H. et al. Compliance as an Explanatory Variable in Hepatitis-C. Ther Innov Regul Sci 35, 1351–1361 (2001).

Download citation

Key Words

  • Compliance
  • Dose-response
  • Hepatitis C
  • Interferon
  • Ribavirin